FDA picks accelerated approval path to decide in favor of Biogen Alzheimer’s drug June 7, 2021 Auto Bot Aduhelm, alzheimer's disease, Biogen, BioPharma, biopharma nl, Cambridge, Clinical Trials, FDA, Massachusetts, Pharma 0 A Biogen Alzheimer’s drug that clears amyloid plaque from the brain has been granted accelerated approved by the FDA. The drug, which will be marketed as Aduhelm, is the first new FDA-approved Alzheimer’s treatment since 2003.